Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Proteins & Peptides
Filter     Order     Display # 
Date Item Title
21 Feb 2006 CuraGen Announces Phase II Results on Velafermin for the Prevention of Oral Mucositis at 2006 BMT Tandem Meetings
21 Feb 2006 Viragen's Multiferon(R) Approved in Sweden for First-Line Adjuvant Treatment of Malignant Melanoma
17 Feb 2006 3 New Studies Show Hemispherx Biopharma’s Ampligen® and Alferon® LDO May Provide Defense Against Avian Flu
16 Feb 2006 Dana-Farber Cancer Institute to Investigate Chemokine Therapeutics' CTCE-9908 in a Preclinical Study of Human Brain Cancer
15 Feb 2006 Biolex Therapeutics Presents Results Highlighting Benefits of Locteron(TM) at 'Breakthroughs in Hepatitis' Session
15 Feb 2006 Bioms Medical secures long-term manufacturing agreements for multiple sclerosis drug
14 Feb 2006 Scil Technology Enrols First Patient in Phase II Sinus Lift Study
14 Feb 2006 Neose Technologies Initiates Phase I Trial of NE-180
13 Feb 2006 Affymax and Takeda Announce Agreement To Develop and Commercialize Hematide™ in Japan
11 Feb 2006 Cangene receives continued funding from Canadian government for development of therapy for acute radiation syndrome
10 Feb 2006 Positive Pre-Clinical Data on Two New Investigational HIV Fusion Inhibitors Presented at Major Scientific Meeting
10 Feb 2006 Pramlintide Obesity Study Results Positive
10 Feb 2006 Neose Receives Milestone Payment from Novo Nordisk Under Expanded Agreement
09 Feb 2006 Zelos Therapeutics Completes Enrollment in Two Ostabolin-C Phase 2 Clinical Trials
09 Feb 2006 Gastrotech Initiates New Clinical Phase II Cancer Cachexia Study
09 Feb 2006 Bayer and Global Regulatory Authorities Evaluating Published Reports on Trasylol
08 Feb 2006 Viragen Reports on Multiferon® Anti-Viral Studies with U.S. Army Researchers
08 Feb 2006 Halozyme Therapeutics and Baxter Release Results From the INFUSE-LR Study
07 Feb 2006 BioMS Medical's pivotal Multiple Sclerosis trial receives third positive review from Data Safety Monitoring Board
07 Feb 2006 Celtic Pharma and Neurobiological Technologies Announce Initiation of Second Pivotal Phase III Clinical Trial for XERECEPT®, a Therapy for Peritumoral Brain Edema
07 Feb 2006 Chemokine Therapeutics Receives Approval From Regulatory Authorities to Initiate Phase Ib/II Human Clinical Trial for its Anti Cancer Drug, CTCE-9908
03 Feb 2006 InterMune Discontinues Ovarian Cancer Trial
03 Feb 2006 Halozyme Therapeutics Initiates Clinical Trial of Subcutaneous Morphine With Hylenex
03 Feb 2006 Eurand Initiates the First of Two Phase 3 Studies for EUR-1008M In Patients With Pancreatic Insufficiency
03 Feb 2006 Regeneron’s VEGF Trap Demonstrates Positive Preliminary Results In Patients With Age-Related Macular Degeneration
03 Feb 2006 Regeneron’s VEGF Trap Demonstrates Positive Preliminary Results In Patients With Age-Related Macular Degeneration
01 Feb 2006 Nastech Pharmaceutical Company Inc. and Procter & Gamble Announce Collaboration to Develop and Commercialize Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis
01 Feb 2006 Lorus announces the presentation of Virulizin(R) Phase III clinical trial results in pancreatic cancer including new data from an exploratory analysis
01 Feb 2006 Microbix takes over production of urokinase, and is currently negotiating the exclusive right to manufacture the drug for a new proprietary use
01 Feb 2006 GeoPharma In-Licenses Pulmonary Hypertension Compound for Development
31 Jan 2006 Æterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights for Cetrorelix in Benign Prostate Hyperplasia
31 Jan 2006 BioMarin Receives Marketing Approval for Naglazyme in European Union
30 Jan 2006 Affymax begins phase 2 clinical trial of Hematide™ in patients with anemia associated with cancer and cancer chemotherapy
30 Jan 2006 Alfacell Revises Guidance on Patient Enrollment for the ONCONASE Confirmatory Phase IIIb Clinical Trial in Unresectable Malignant Mesothelioma
28 Jan 2006 Pfizer Receives FDA Approval for Exubera, the First Inhalable Form of Insulin for Controlling Type 1 and Type 2 Diabetes in Adults
27 Jan 2006 Myozyme® Receives Positive Opinion from European Regulatory Committee
27 Jan 2006 Bayer Clinical Trials on Trasylol Not Consistent with New England Journal of Medicine (NEJM) Study
27 Jan 2006 European Commission Approves Exubera® (Inhaled Human Insulin) for Treatment of Type 1 and Type 2 Diabetes
26 Jan 2006 ConjuChem's PC-DAC(TM):Exendin-4 Advancing into Human Clinical Testing For Type 2 Diabetes
26 Jan 2006 ConjuChem's PC-DAC(TM):Exendin-4 Advancing into Human Clinical Testing For Type 2 Diabetes
26 Jan 2006 CepTor Receives Dual Orphan Drug Designation for Myodur (C101) for
25 Jan 2006 Halozyme Therapeutics Completes Enrollment of INFUSE-LR, a Hylenex Clinical Trial of Subcutaneous Hydration
25 Jan 2006 Lab International announces final cgrp phase I pharmacokinetic results
24 Jan 2006 Serono's gonal-f® approved in japan for the treatment of male hypogonadotropic hypogonadism
24 Jan 2006 Biovitrum and Syntonix enter agreement for the joint development and commercialization of recombinant Factor IX for the treatment of Hemophilia
24 Jan 2006 Recent Study Confirms REGRANEX® (Becaplermin) Gel To Be Effective Treatment Of Diabetic Neuropathic Foot Ulcers
23 Jan 2006 Nuvelo Receives FDA Fast Track Status for Alfimeprase
12 Jan 2006 Scil Technology Establishes Proof of Concept with Proprietary Cartilage Repair Technology
09 Jan 2006 Alkermes and Lilly Announce Agreement for the Development and Commercialization of Inhaled Parathyro
12 Dec 2005 CEL-SCI Signs Agreement With U.S. Government Institute for Testing of Drug Against Avian Flu Virus H
 
<< Start < Prev 21 22 23 24 25 26 27 Next > End >>
Results 1251 - 1300 of 1301

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Thrombopoiesis-Stimulating Agents (TPO)

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics